UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or o ...

Financial Performance - Esperion Therapeutics (ESPR) reported a loss of $0.02 per share in Q2 2025, significantly better than the Zacks Consensus Estimate of a loss of $0.17 and an improvement from a loss of $0.05 in the same quarter last year [1][6] - Total revenues for Q2 reached $82.4 million, marking a 12% year-over-year increase and surpassing the Zacks Consensus Estimate of $66 million [1][6] - U.S. product revenues totaled $40.3 million, up 42% year-over-year, exceeding the Zacks Consensus Estimate of $35.1 million [4][6] Revenue Breakdown - Collaboration revenues, which include royalties and partner revenues, amounted to $42.1 million, down nearly 7% year-over-year due to a milestone payment recorded in the previous year, but excluding this, collaboration revenues surged approximately 105% year-over-year [7][8] - The company achieved its first-ever operating income from ongoing business operations in Q2 2025 [9] Cost Management - Research and development expenses decreased by 37% year-over-year to $7.2 million, reflecting reduced costs in ongoing clinical studies [8] - Selling, general, and administrative expenses fell by 11% year-over-year to $39.5 million due to lower media and marketing costs [8] Future Outlook - Esperion expects operating expenses for 2025 to be in the range of $215-$235 million, including $15 million in non-cash stock compensation expenses [10] - The company anticipates achieving sustainable profitability starting in Q1 2026 [10] Recent Developments - Esperion reached settlement agreements with three ANDA filers regarding patents for Nexletol, preventing the marketing of generic versions until 2040, which is expected to protect future U.S. sales [11]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 grew 12% year over year to $82.4 million, despite a $25 million one-time milestone payment in Q2 2024, indicating strong underlying business performance [20][21] - U.S. net product revenue increased 42% year over year to $40.3 million and grew 15% sequentially [21] - Operating income from ongoing business reached approximately $15 million, marking the first quarter of operating income in the company's history [5][19] Business Line Data and Key Metrics Changes - Collaboration revenue decreased by approximately 7% to $42.1 million, impacted by a settlement agreement milestone with DSC, but grew 105% when excluding this milestone [21][22] - Research and development expenses decreased by 37% to $7.25 million, while selling, general, and administrative expenses decreased by 11% to $39.5 million [22] Market Data and Key Metrics Changes - The company reported over 650,000 visits to its consumer statin intolerance website and more than 600,000 click-throughs to its physician site during Q2 [8] - The total prescriber base increased to over 28,000 healthcare practitioners, with a 10% increase in total retail prescription equivalents [10][21] Company Strategy and Development Direction - The company is focused on expanding its cardiovascular risk reduction portfolio, including plans to develop a triple combination product [12][13] - The marketing strategy emphasizes reaching statin intolerant patients, with successful campaigns like "Can't take a statin, make NexoZet happen" driving brand awareness [7][12] - The company aims to transition to sustainable profitability starting in 2026, supported by strong operational results and global growth [19][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustainable profitability due to strong performance and ongoing global growth [19][25] - The endorsement of NEXLETOL and NEXLASET by leading cardiovascular professional societies is seen as a validation of the company's science and marketing efforts [7][12] - Management highlighted the importance of digital marketing and consumer engagement in driving growth and awareness [9][11] Other Important Information - The company reached settlement agreements with three generic manufacturers to delay the marketing of generic versions of Nexletol until February 2040 [13] - The company is advancing its pipeline, including a program targeting primary sclerosing cholangitis, which represents a significant market opportunity [14] Q&A Session Summary Question: What is the status of prior authorizations relative to the total addressable market for the product? - Management reported over 80% approval rates for prior authorizations, with some regions achieving even higher rates [29][30] Question: What will the working capital benefits from the transfer to DSC look like on the balance sheet? - The company expects to ramp down inventory production as DSC takes over, with inventory decreasing in the second half of the year [31][32] Question: What drove the significant growth from April to May? - The growth was attributed to the strategy targeting statin intolerant patients and increased awareness through marketing campaigns [36][37] Question: How does the company view consensus U.S. revenue for the year? - Management indicated they are tracking well ahead of consensus and expect to achieve milestone payments in the second half of the year [44][45] Question: What is the outlook for gross margin trends in the back half of the year? - Management expects benefits from the tech transfer to kick in early next year, with steady favorable gross to net ratios anticipated [51][55] Question: How will Nexletol remain competitive in the non-statin LDL space? - The company highlighted its unique position as the only product studied in statin intolerant patients and its strong patent position [60][62]

Q2 2025 Earnings Presentation August 5, 2025 © 2025 Esperion Therapeutics, Inc. All rights reserved. Forward-looking Statements & Disclosures This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, expected profitability, future operations, commercial products, clinical development, plans for poten ...

Exhibit 99.1 Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update – Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL (bempedoic acid) Prior to 2040 – ® – First Quarter of Operating Income from Ongoing Business with Plans for Sustainable ...

Core Insights - Esperion has entered into a settlement agreement with Accord Healthcare Inc. to resolve patent litigation regarding the generic version of NEXLETOL, preventing Accord from marketing it in the U.S. before April 19, 2040, under certain conditions [1] - Ongoing patent litigation against other defendants related to NEXLETOL and NEXLIZET continues, with no assurance on the outcome regarding the marketing of generics before the same date [2] Company Overview - Esperion Therapeutics is a biopharmaceutical company focused on developing and commercializing FDA-approved oral, once-daily, non-statin medications for patients at risk of cardiovascular disease with elevated LDL-C levels, supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients [3] - The company is advancing its pre-clinical pipeline and developing next-generation ATP citrate lyase inhibitors (ACLYi) to create highly potent and specific inhibitors [3][4]

Business Overview - U.S net product revenue of NEXLETOL® and NEXLIZET® grew by 12% from Q3 2021 to $12.2 million in Q4 2021[10] - Sequential prescription growth of 9% from Q3 2021 with over 70,000 cumulative patients[10] - CLEAR Outcomes trial reached 90% MACE Accumulation in February 2022, with topline results expected in Q1 2023[10, 16] Financial Update - Ended Q4 2021 with $309.3 million in cash, cash equivalents, restricted cash and investment securities[10] - FY 2021 Operating Expenses were $305 million[22] - FY 2022 R&D Guidance is $100 - $110 million[22] - FY 2022 SG&A Guidance is $120 - $130 million[22] - Future Ex-U.S Collaboration Milestones from Daiichi Sankyo & Otsuka are >$1.2 billion[22] - Q4 2021 Common Shares Outstanding were 60.9 million[22]

Business Highlights - Approximately 35 million patients are considered statin intolerant in the U S, Japan, and the EU[8] - Statin intolerance impacts up to 20% of individuals treated with a statin[8, 12] - CLEAR Outcomes trial has enrolled over 14,000 patients and is powered for success[12] - The CLEAR Outcomes trial expects a high baseline LDL-C of approximately 140 mg/dL[12] Operational Performance - Over 8,600 doctors are writing at least one prescription for Esperion's medicines[15] - More than 3,300 patients are taking Esperion's medicines every week[15] - Over 420,000 seven-day starter packs have been requested and received[15] - New-to-brand statin prescriptions are down 9% year-to-date 2021 compared to year-to-date 2020 due to COVID-19 impacts[17] Financial Results & Guidance - U S Net Product Sales increased 14 6% quarter over quarter[23] - Royalty revenues from DSE were $8 2 million in the quarter[23] - Ex-U S Collaboration Milestones were $3 3 million[23] - The company anticipates FY 2021 revenues between $120 - $130 million[26]

Financial Performance - U S net product revenue of NEXLETOL® and NEXLIZET® grew approximately 109% year-over-year to $134 million in Q1 2022[9, 27] - Royalty and Partner revenue increased approximately 244% year-over-year to $55 million in Q1 2022[9] - Q1 2022 Operational Expenses decreased 32% year-over-year[9] - The company ended Q1 2022 with $2685 million in cash, cash equivalents, restricted cash, and investment securities[9] Prescription Growth - Quarterly Retail Prescription Equivalents (RPE) grew +567% year-over-year and +65% quarter-over-quarter[9] Clinical Trial Progress - The CLEAR Outcomes trial is approaching 95% MACE accumulation, with 100% MACE expected by year-end and topline results anticipated in Q1 2023[9, 20] - The CLEAR Outcomes trial is a 14,014-patient randomized, double-blind, placebo-controlled clinical trial with a median follow-up anticipated to be 375 years[20] Market Opportunity - The company is progressing its pipeline, including an oral PCSK9 inhibitor and an ACL inhibitor platform, which will participate in a market valued at over $11 billion in 2026[19] Financial Outlook - FY 2022 Research and Development (R&D) guidance is $100 - $110 million[27] - FY 2022 Selling, General & Administrative (SG&A) guidance is $120 - $130 million[27] - FY 2022 Operating Expense (Op Ex) guidance is $220 - $240 million[27]

Company Overview & Strategy - Esperion is evolving into a global cardiometabolic biotech, advancing the CLEAR Outcomes trial and pre-clinical pipeline assets [6] - The company restructured and financed in 2021 to reduce cost burn and strengthen the cash balance [9] - Esperion launched two approved drugs in Q2 2020 in the U S, with strong IP protection anticipated until mid-2031 [9] Market & Products - Nearly 80% of very high-risk patients in the U S did not meet guideline-recommended LDL-C goals [18] - 8.7 million patients in the U S don't reach their LDL-C goals despite taking a statin, while 9.6 million with high LDL-C are not on statins [18] - Up to 20% of people who could be treated with a statin experience statin intolerance [18] - NEXLETOL & NEXLIZET are safe & well-tolerated oral options for LDL-C lowering [30] Financial Performance & Outlook - Q1 2022 U S revenue was $13.4 million [35] - Esperion has >$1.2 billion in potential future ex-U S collaboration milestones from Daiichi Sankyo & Otsuka [67] - Esperion's Q1 2022 cash, cash equivalents, restricted cash & investment securities available-for-sale totaled $268.5 million [67] Clinical Development - The CLEAR Outcomes trial is approaching 100% MACE accumulation in 2H 2022, with top-line results anticipated in Q1 2023 [43] - Over 14,000 patients in 32 countries are fully enrolled in the CLEAR Outcomes trial [44]